First open-label, single-arm, prospective study of real-world use of FIX replacement therapy in a predominantly pediatric hemophilia B population in China

BACKGROUND: Nonacog alfa (recombinant factor IX [FIX]) is approved in China for the control and prevention of bleeding events in patients with hemophilia B. This was the first study to assess prophylaxis and on-demand therapy with recombinant FIX replacement in a real-world setting in China. This st...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Renchi, Wu, Runhui, Sun, Jing, Sun, Feifei, Rupon, Jeremy, Huard, Francois, Korth-Bradley, Joan M., Xu, Lihong, Luo, Binyu, Liu, Yingxue Cathy, Rendo, Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
4800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154445/
https://www.ncbi.nlm.nih.gov/pubmed/34032739
http://dx.doi.org/10.1097/MD.0000000000026077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154445/
https://www.ncbi.nlm.nih.gov/pubmed/34032739
http://dx.doi.org/10.1097/MD.0000000000026077

Ejemplares similares